Rainbow Seed Fund News

 Cambridge and Newcastle, UK, 06 January 2021 – Atelerix Ltd (Atelerix) announces the appointment of a new CEO as the company accelerates its growth programme. Over the last four years, the company has been led by co-founder and CEO, Mick McLean, as it developed its products and started commercialisation of its innovative cell encapsulation technology. […]

read more

Coventry, UK, 10th December 2020 / NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. NanoSyrinx is an early-stage biotechnology company using synthetic biology approaches to develop a completely novel platform for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells. Dr Dancer has over 30 years’ experience […]

read more

Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect. Pavel Pisa is the former Head of Translational Medicine at Roche and Genentech and has led […]

read more

1 2 3 4